Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biotest AG M&A Activity 2004

Mar 10, 2004

66_rns_2004-03-10_2d0a8cdb-37d9-435e-997c-e0505e33f912.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Corporate | 10 March 2004 09:00

Biotest sells its shareholding in SIFIN

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Biotest sells its shareholding in SIFIN Dreieich, March 10, 2004. The pharmaceutical and diagnostics company Biotest AG has sold its 26 % interest in SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin to the company’s majority shareholder. The Institute, which was formed from a former East German state company, specialises in microbiological diagnostics and monoclonal antibodies. With these areas of activity SIFIN has recently only been on the sidelines in terms of Biotest’s range of products and interests. The sale of SIFIN is a continuation of Biotest’s new strategic direction started last year. Biotest AG The Board of Management end of message, (c)DGAP 10.03.2004 ——————————————————————————– WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 100900 Mär 04